Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
Lancet (London, England)
|
October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Claire L Vale, David Fisher, Andrew Kneebone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Gerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
JAMA Oncology
|
January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial
Nicholas D James, Sarah J Pirrie, Ann M Pope, et al.
The Lancet. Oncology
|
May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor, Robert Coleman, Sten Nilsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Cancer Research
|
April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer
Gerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
The Lancet. Neurology
|
May 30, 2020
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis
Rachael I Scahill, Paul Zeun, Katherine Osborne-Crowley, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 15, 2022
No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity
Gillian C Barnett, Sarah L Kerns, Leila Dorling, et al.
The New England Journal of Medicine
|
March 25, 2026
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer
Ruth E Langley, Duncan C Gilbert, Stephen Mangar, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
Lancet (London, England)
|
October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Claire L Vale, David Fisher, Andrew Kneebone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Gerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
JAMA Oncology
|
January 23, 2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial
Nicholas D James, Sarah J Pirrie, Ann M Pope, et al.
The Lancet. Oncology
|
May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor, Robert Coleman, Sten Nilsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Cancer Research
|
April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer
Gerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
The Lancet. Neurology
|
May 30, 2020
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis
Rachael I Scahill, Paul Zeun, Katherine Osborne-Crowley, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 15, 2022
No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity
Gillian C Barnett, Sarah L Kerns, Leila Dorling, et al.
The New England Journal of Medicine
|
March 25, 2026
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer
Ruth E Langley, Duncan C Gilbert, Stephen Mangar, et al.
Page
of 8